Oscar Health Valuation After Raymond James Upgrade And Margin Expansion Outlook

Oscar Health (OSCR) recently received an Outperform upgrade from Raymond James, driven by expectations of margin expansion in the Affordable Care Act exchange market and improved administrative efficiency. Despite recent share price fluctuations, the stock is trading at an approximately 18% discount to the analyst price target of US$15.40, with a fair value estimated at $15.78, suggesting it is undervalued. The increased fair value is attributed to updated pricing work, benefit design, and resilient exchange enrollment, though policy changes and industry consolidation remain potential risks.